Pancreatic Cancer Research

ResearcherMedical University of WarsawActive in the last 2 years

Andrzej Deptała

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2640-2043; OpenAlex author ID A5045513298. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
13
Papers, trials and grants by year

2022: 1 paper · 2023: 7 papers · 2024: none · 2025: 5 papers · 2026: 3 papers

Papers 16

  1. Can liver-associated parameters serve as prognostic factors in pancreatic cancer? - A retrospective analysis of a large-capacity centre. Last author DOI 10.1016/j.advms.2026.02.001↗
  2. From Physiology to Clinical Practice in Pancreatic Cancer-Related Thromboembolism-A Review. Co-author DOI 10.3390/cancers18060890↗
  3. Comparison of pre-treatment systemic inflammation indices (systemic immune-inflammation index, systemic inflammation response index, and inflammatory benchmark… Last author DOI 10.5114/wo.2026.159587↗
  4. Inflammation, Immunosuppression, and Immunotherapy in Pancreatic Cancer-Where Are We Now? Last author DOI 10.3390/cancers17091484↗
  5. The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma: Recent Advancements and Emerging Therapeutic Strategies. Co-author DOI 10.3390/cancers17101599↗
  6. Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients? Last author DOI 10.3390/cancers17152453↗
  7. Neoadjuvant Therapy or Upfront Surgery for Pancreatic Cancer-To Whom, When, and How? Last author DOI 10.3390/cancers17152584↗
  8. KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities? Last author DOI 10.3390/cancers17233769↗
  9. Treatment Costs and Social Burden of Pancreatic Cancer. Last author DOI 10.3390/cancers15061911↗
  10. New Treatment Options in Metastatic Pancreatic Cancer. Last author DOI 10.3390/cancers15082327↗
  11. Overview of Pancreatic Cancer Epidemiology in Europe and Recommendations for Screening in High-Risk Populations. Co-author DOI 10.3390/cancers15143634↗
  12. Evaluation of Nutritional Status and the Impact of Nutritional Treatment in Patients with Pancreatic Cancer. Last author DOI 10.3390/cancers15153816↗
  13. How A Patient with Resectable or Borderline Resectable Pancreatic Cancer should Be Treated-A Comprehensive Review. Last author DOI 10.3390/cancers15174275↗
  14. Management of Metastatic Pancreatic Cancer-Comparison of Global Guidelines over the Last 5 Years. Co-author DOI 10.3390/cancers15174400↗
  15. Quality of Life in Patients with Pancreatic Cancer-A Literature Review. Last author DOI 10.3390/ijerph20064895↗
  16. Diabetes Mellitus and Pancreatic Ductal Adenocarcinoma-Prevalence, Clinicopathological Variables, and Clinical Outcomes. Last author DOI 10.3390/cancers14122840↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anna Maria Badowska-Kozakiewicz · 13 shared papers, 2022–2026 · strength 3.57
  2. Marta Magdalena Fudalej · 12 shared papers, 2022–2026 · strength 3.38
  3. Daria Kwaśniewska · 6 shared papers, 2022–2026 · strength 1.42
  4. Kamila Krupa · 4 shared papers, 2025–2026 · strength 1.18
  5. Elżbieta Cipora · 6 shared papers, 2023 · strength 0.94
  6. Dominika Mękal · 4 shared papers, 2023–2025 · strength 0.79
  7. Olga Partyka · 4 shared papers, 2023 · strength 0.56
  8. Monika Pajewska · 4 shared papers, 2023 · strength 0.56
  9. Remigiusz Kozłowski · 3 shared papers, 2023–2025 · strength 0.54
  10. Monika Jarowicz · 1 shared paper, 2026 · strength 0.29
  11. Franciszek Glapiński · 1 shared paper, 2025 · strength 0.27
  12. Michał Marczak · 2 shared papers, 2023 · strength 0.27
  13. Marek Durlik · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.